{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    6,
    7,
    8,
    9,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "Treatment Arm A (Placebo + BR)",
        "type": {
          "code": "Placebo Comparator Arm",
          "codeSystem": "USDM",
          "decode": "Placebo Comparator Arm"
        },
        "instanceType": "StudyArm",
        "description": "Placebo capsules administered orally once daily continuously in combination with bendamustine and rituximab (BR) for 6 cycles, followed by rituximab maintenance for responders."
      },
      {
        "id": "arm_2",
        "name": "Treatment Arm B (Ibrutinib + BR)",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Ibrutinib 560 mg administered orally once daily continuously in combination with bendamustine and rituximab (BR) for 6 cycles, followed by rituximab maintenance for responders."
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_1"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_2"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_3"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_1",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_4"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_1",
        "epochId": "epoch_5",
        "elementIds": [
          "elem_5"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_6",
        "armId": "arm_1",
        "epochId": "epoch_6",
        "elementIds": [
          "elem_6"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_7",
        "armId": "arm_2",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_7"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_8",
        "armId": "arm_2",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_8"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_9",
        "armId": "arm_2",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_9"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_10",
        "armId": "arm_2",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_10"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_11",
        "armId": "arm_2",
        "epochId": "epoch_5",
        "elementIds": [
          "elem_11"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_12",
        "armId": "arm_2",
        "epochId": "epoch_6",
        "elementIds": [
          "elem_12"
        ],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [],
    "studyElements": [
      {
        "id": "elem_1",
        "name": "Treatment Arm A (Placebo + BR) - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Treatment Arm A (Placebo + BR) during Screening"
      },
      {
        "id": "elem_2",
        "name": "Treatment Arm A (Placebo + BR) - BR Treatment Period (Cycles 1 to 6)",
        "instanceType": "StudyElement",
        "description": "Treatment period for Treatment Arm A (Placebo + BR) during BR Treatment Period (Cycles 1 to 6)"
      },
      {
        "id": "elem_3",
        "name": "Treatment Arm A (Placebo + BR) - R Maintenance Period (Cycles 8 to 30)",
        "instanceType": "StudyElement",
        "description": "Treatment period for Treatment Arm A (Placebo + BR) during R Maintenance Period (Cycles 8 to 30)"
      },
      {
        "id": "elem_4",
        "name": "Treatment Arm A (Placebo + BR) - Post-Cycle 30 / Continuous Treatment",
        "instanceType": "StudyElement",
        "description": "Treatment period for Treatment Arm A (Placebo + BR) during Post-Cycle 30 / Continuous Treatment"
      },
      {
        "id": "elem_5",
        "name": "Treatment Arm A (Placebo + BR) - End of Treatment Visit",
        "instanceType": "StudyElement",
        "description": "Treatment period for Treatment Arm A (Placebo + BR) during End of Treatment Visit"
      },
      {
        "id": "elem_6",
        "name": "Treatment Arm A (Placebo + BR) - Posttreatment Follow-up Phase",
        "instanceType": "StudyElement",
        "description": "Treatment period for Treatment Arm A (Placebo + BR) during Posttreatment Follow-up Phase"
      },
      {
        "id": "elem_7",
        "name": "Treatment Arm B (Ibrutinib + BR) - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Treatment Arm B (Ibrutinib + BR) during Screening"
      },
      {
        "id": "elem_8",
        "name": "Treatment Arm B (Ibrutinib + BR) - BR Treatment Period (Cycles 1 to 6)",
        "instanceType": "StudyElement",
        "description": "Treatment period for Treatment Arm B (Ibrutinib + BR) during BR Treatment Period (Cycles 1 to 6)"
      },
      {
        "id": "elem_9",
        "name": "Treatment Arm B (Ibrutinib + BR) - R Maintenance Period (Cycles 8 to 30)",
        "instanceType": "StudyElement",
        "description": "Treatment period for Treatment Arm B (Ibrutinib + BR) during R Maintenance Period (Cycles 8 to 30)"
      },
      {
        "id": "elem_10",
        "name": "Treatment Arm B (Ibrutinib + BR) - Post-Cycle 30 / Continuous Treatment",
        "instanceType": "StudyElement",
        "description": "Treatment period for Treatment Arm B (Ibrutinib + BR) during Post-Cycle 30 / Continuous Treatment"
      },
      {
        "id": "elem_11",
        "name": "Treatment Arm B (Ibrutinib + BR) - End of Treatment Visit",
        "instanceType": "StudyElement",
        "description": "Treatment period for Treatment Arm B (Ibrutinib + BR) during End of Treatment Visit"
      },
      {
        "id": "elem_12",
        "name": "Treatment Arm B (Ibrutinib + BR) - Posttreatment Follow-up Phase",
        "instanceType": "StudyElement",
        "description": "Treatment period for Treatment Arm B (Ibrutinib + BR) during Posttreatment Follow-up Phase"
      }
    ],
    "summary": {
      "armCount": 2,
      "cellCount": 12,
      "cohortCount": 0,
      "elementCount": 12
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Double Blind",
        "codeSystem": "USDM",
        "decode": "Double Blind"
      },
      "maskedRoles": [
        "Subject",
        "Investigator"
      ],
      "randomizationType": {
        "code": "Randomized",
        "codeSystem": "USDM",
        "decode": "Randomized"
      },
      "allocationRatio": {
        "ratio": "1:1"
      },
      "stratificationFactors": [
        "Simplified Mantle Cell Lymphoma International Prognostic Index (MIPI) score"
      ],
      "controlType": {
        "code": "Placebo Control",
        "codeSystem": "USDM",
        "decode": "Placebo Control"
      },
      "armIds": [
        "arm_1",
        "arm_2"
      ],
      "therapeuticAreas": [
        "Oncology",
        "Hematology"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Double Blind",
        "maskedRoles": [
          "Subject",
          "Investigator"
        ]
      },
      "randomization": {
        "type": "Randomized",
        "allocationRatio": "1:1",
        "stratificationFactors": [
          "Simplified Mantle Cell Lymphoma International Prognostic Index (MIPI) score"
        ]
      },
      "controlType": "Placebo",
      "therapeuticAreas": [
        "Oncology",
        "Hematology"
      ]
    },
    "arms": [
      {
        "name": "Treatment Arm A (Placebo + BR)",
        "type": "Placebo Comparator",
        "description": "Placebo capsules administered orally once daily continuously in combination with bendamustine and rituximab (BR) for 6 cycles, followed by rituximab maintenance for responders.",
        "isTitration": false
      },
      {
        "name": "Treatment Arm B (Ibrutinib + BR)",
        "type": "Experimental Arm",
        "description": "Ibrutinib 560 mg administered orally once daily continuously in combination with bendamustine and rituximab (BR) for 6 cycles, followed by rituximab maintenance for responders.",
        "isTitration": false
      }
    ],
    "cohorts": [],
    "epochs": [
      {
        "name": "Screening",
        "description": "Up to 30 days prior to randomization"
      },
      {
        "name": "BR Treatment Period (Cycles 1 to 6)",
        "description": "Bendamustine (Days 1, 2) and Rituximab (Day 1) every 28 days for up to 6 cycles plus daily study drug/placebo"
      },
      {
        "name": "R Maintenance Period (Cycles 8 to 30)",
        "description": "For subjects with CR or PR: Rituximab every second cycle (every 8 weeks) for up to 12 additional doses plus daily study drug/placebo"
      },
      {
        "name": "Post-Cycle 30 / Continuous Treatment",
        "description": "Continuous daily study drug/placebo until disease progression or unacceptable toxicity"
      },
      {
        "name": "End of Treatment Visit",
        "description": "Within 30 days after the last dose of the last study treatment"
      },
      {
        "name": "Posttreatment Follow-up Phase",
        "description": "Follow-up until progressive disease and subsequent survival follow-up"
      }
    ]
  }
}